Literature DB >> 21658164

Abnormal expression of dysferlin in skeletal muscle and monocytes supports primary dysferlinopathy in patients with one mutated allele.

M Meznaric1, L Gonzalez-Quereda, E Gallardo, N de Luna, P Gallano, M Fanin, C Angelini, B Peterlin, J Zidar.   

Abstract

BACKGROUND: In some cases, a definitive confirmation of dysferlinopathy cannot be achieved by DNA test, because the mutation is detected in one allele only. PATIENTS AND METHODS: DYSFERLIN expression in skeletal muscle and peripheral blood monocytes (PBM) was studied by Western blot in two unrelated adult patients. The comparative C(T) method (ΔΔC(T) ) was used to calculate relative changes in dysferlin mRNA determined from real-time quantitative PCR experiments. The dysferlin gene was studied by direct sequencing of cDNA and genomic DNA and by Multiplex Ligation-dependent Probe Amplification (MLPA) analysis.
RESULTS: A comparable severe reduction in dysferlin was demonstrated in both skeletal muscle and PBM. The expression of dysferlin mRNA was significantly reduced. A novel mutation in exon 47 (c.5289G>C) of the dysferlin gene in the heterozygous state, causing an amino acid change (p.Glu1763Asp), was detected in both patients. The MLPA analysis did not reveal any deletion or duplication.
CONCLUSIONS: Dysferlin and/or dysferlin mRNA abnormalities are diagnostic for dysferlinopathy when mutational analysis detects a mutation in one allele only. Analysis of dysferlin mRNA can be helpful for distinguishing symptomatic heterozygotes from such patients.
© 2010 The Author(s). European Journal of Neurology © 2010 EFNS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21658164     DOI: 10.1111/j.1468-1331.2010.03240.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  5 in total

1.  Taking advantage of an old concept, "illegitimate transcription", for a proposed novel method of genetic diagnosis of McArdle disease.

Authors:  Ines Garcia-Consuegra; Alberto Blázquez; Juan Carlos Rubio; Joaquín Arenas; Alfonsina Ballester-Lopez; Adrián González-Quintana; Antoni L Andreu; Tomàs Pinós; Jaume Coll-Cantí; Alejandro Lucia; Gisela Nogales-Gadea; Miguel A Martín
Journal:  Genet Med       Date:  2016-02-25       Impact factor: 8.822

2.  The EuroBioBank Network: 10 years of hands-on experience of collaborative, transnational biobanking for rare diseases.

Authors:  Marina Mora; Corrado Angelini; Fabrizia Bignami; Anne-Mary Bodin; Marco Crimi; Jeanne-Hélène Di Donato; Alex Felice; Cécile Jaeger; Veronika Karcagi; Yann LeCam; Stephen Lynn; Marija Meznaric; Maurizio Moggio; Lucia Monaco; Luisa Politano; Manuel Posada de la Paz; Safaa Saker; Peter Schneiderat; Monica Ensini; Barbara Garavaglia; David Gurwitz; Diana Johnson; Francesco Muntoni; Jack Puymirat; Mojgan Reza; Thomas Voit; Chiara Baldo; Franca Dagna Bricarelli; Stefano Goldwurm; Giuseppe Merla; Elena Pegoraro; Alessandra Renieri; Kurt Zatloukal; Mirella Filocamo; Hanns Lochmüller
Journal:  Eur J Hum Genet       Date:  2014-12-24       Impact factor: 4.246

3.  Serum exosomes can restore cellular function in vitro and be used for diagnosis in dysferlinopathy.

Authors:  Xue Dong; Xianjun Gao; Yi Dai; Ning Ran; HaiFang Yin
Journal:  Theranostics       Date:  2018-02-02       Impact factor: 11.556

4.  Exome sequencing identifies novel dysferlin mutation in a family with pauci-symptomatic heterozygous carriers.

Authors:  Mahjoubeh Jalali-Sefid-Dashti; Melissa Nel; Jeannine M Heckmann; Junaid Gamieldien
Journal:  BMC Med Genet       Date:  2018-06-07       Impact factor: 2.103

5.  LGMD phenotype due to a new gene and dysferlinopathy investigated by next-generation sequencing.

Authors:  Corrado I Angelini
Journal:  Neurol Genet       Date:  2015-12-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.